Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has issued an update.
Shanghai Junshi Biosciences Co., Ltd. announced that its phase III clinical study of JS001sc, a subcutaneous injection formulation for the first-line treatment of non-squamous non-small cell lung cancer (NSCLC), has met its primary endpoints. This development marks a significant step in providing a more convenient administration method for immunotherapy, potentially enhancing patient experience and positioning the company as a leader in domestic anti-PD-1 monoclonal antibody treatments. The company plans to submit a new drug application to regulatory authorities, which could impact its market presence and offer new options for NSCLC patients.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$20.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a Chinese pharmaceutical company specializing in the development of innovative drugs, particularly focusing on immunotherapy treatments such as anti-PD-1 monoclonal antibodies. The company aims to address the clinical need for more convenient cancer treatments.
Average Trading Volume: 6,952,422
Technical Sentiment Signal: Buy
Current Market Cap: HK$36.08B
Learn more about 1877 stock on TipRanks’ Stock Analysis page.